Ifosfamide in the treatment of malignant epithelial ovarian tumors

Oncology

Volumn 65, Issue SUPPL. 2, 2003, Pages 59-62

  Lissoni, A A ^a   Fei, F ^a   Rossi, R ^a   Fruscio, R ^a   Villa, A ^a   Zani, G ^a  

^a SAN GERARDO HOSPITAL   (Italy)

Author keywords

Combination chemotherapy; Epithelial ovarian cancer; Gynecological sarcomas; Ifosfamide

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; CARBOPLATIN; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; IFOSFAMIDE; MELPHALAN; MESNA; PACLITAXEL; TAXANE DERIVATIVE; THIOTEPA;

ACUTE KIDNEY FAILURE; ADVANCED CANCER; ANEMIA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFECT; DRUG MEGADOSE; ENDOMETRIUM SARCOMA; HUMAN; LEIOMYOSARCOMA; META ANALYSIS; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OVARY CARCINOMA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; THROMBOCYTOPENIA; TOXICITY; TREATMENT OUTCOME; UTERUS SARCOMA;

ANTINEOPLASTIC AGENTS, ALKYLATING; CARCINOMA; FEMALE; HUMANS; IFOSFAMIDE; OVARIAN NEOPLASMS; SARCOMA;

EID: 0242351643     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000073361     Document Type: Conference Paper

References (31)

1. Hoskins W, Perez C, Young R: Principles and Practice of Gynecologic Oncology, ed 2. Philadelphia, Lippincott Raven, 1998.
2. Allen LM, Creaven PJ: In vitro activation of isophosphamide (NSC-109724), a new oxazaphosphorine, by rat liver microsomes. Cancer Chemother Rep 1972;56:603.
3. Bonadonna G, Robustelli della Cuna G: Medicina oncologica, ed VI. Milano, Masson, 1987.
4. Goren MP, Wright RK, Pratt CB et al: Clinical pharmacology and efficacy of mesna given to outpatients treated with ifosfamide for solid tumours. Proc Am Soc Clin Oncol 1992;11:272.
5. Mateu J, Alzamora M, Franco M, Buisan MJ: Ifosfamide extravasation. Ann Pharmacother 1994;28:1243.
6. Ozols RF, Young RC: Chemotherapy of ovarian cancer. Semin Oncol 1991;3:222.
7. Wiltshaw E, Krone T: Phase II study of cisdichlorodiammineplatinum. Cancer Treat Rep 1976;60:55.
8. Advanced Ovarian Cancer Trialists Group: Chemotherapy in advanced ovarian cancer: An overview of randomised clinical trials. BMJ 1991;303:884.
9. Guastalla JP, Pujiade-Lauren E, Webber B et al: Efficacy and safety of the paclitaxel and carboplatin combination in patients with previously treated advanced ovarian carcinoma. A Multicenter GIN ECO (Groupe d'investigateurs nationaux pour l'étude de cancer ovarien). Phase II study. Ann Oncol 1998;9:37.
10. Hoskins P, Eisenhauer E, Beare S et al: Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: A National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol 1998;16:2233.
11. Birthe L, Mogens H, Ole PH, Heine HH: Combined high dose carboplatin and cisplatin and ifosfamide in previously untreated ovarian cancer patients with residual disease. J Clin Oncol 1990;8:1226.
12. Omura GA, Bundy BN, Berek JS et al: Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 1989;8:457.
13. Neijt JP, ten Bokkel-Huinink WW, van der Burg MEL et al: Randomized trial comparing two combination chemotherapy regimens (CHAP-5 vs. CP) in advanced ovarian carcinoma. J Clin Oncol 1987;5:1157.
14. Gruppo Interregionale Cooperativo Oncologico Ginecologia: Randomized comparison of cisplatin with cyclophosphamide/cisplatin and with cyclophosphamide/doxorubicin/cisplatin in advanced ovarian cancer. Lancet 1987;ii:353.
15. Araujo CE, Cervellino JC, Pirisi C, Pannunzio O, Callegari J: Chemotherapy with high-dose ifosfamide-mesna plus cisplatin for the treatment of ovarian cancer: A study of the Grupo de Estudio y Tratamiento Latino Americano del Cancer. J Surg Oncol 1991;46:198.
16. Papadimitriou CA, Kouroussis C, Moulopoulos LA, Vlahos G, Rodolakis A, Kiamouris C, Diakomanolis E, Gika D, Michalas S, Dimopoulos MA: Ifosfamide, paclitaxel and cisplatin first-line chemotherapy in advanced, suboptimally debulked epithelial ovarian cancer. Cancer 2001;92:1856.
17. Vallejos C, Solidoro A, Gomez H et al: Ifosfamide plus cisplatin as primary chemotherapy of advanced ovarian cancer. Gynecol Oncol 1997;67:168.
18. Strauss G, Birthe L, Hansen N, Hansen HH: Phase II trial of high-dose cisplatin plus ifosfamide as first-line followed by carboplatin as second-line treatment in epithelial ovarian carcinoma. Gynecol Oncol 1997;66:66.
19. Gallagher CJ, Wiltshaw E, Coleman RE, Harper PG: A dose escalation study of carboplatin and ifosfamide in advanced ovarian cancer. Cancer Chemother Pharmacol 1989;24:54.
20. Markman M, Hakes T, Reichman B et al: Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: Activity in platinum-resistant disease. J Clin Oncol 1992;10:243.
21. Sutton G: Ifosfamide and mesna in epithelial ovarian carcinoma. Gynecol Oncol 1993;51:104.
22. Dobbs SP, Gribbin C, Chan SY et al: Second-line treatment with ifosfamide and carboplatin in patients with ovarian carcinoma relapsing after treatment with carboplatin. Eur J Cancer 1994;30A:30.
23. Sutton GP, Blessing JA, Homesley HD, Berman ML, Malfetano J: Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 1989;7:1672.
24. Marzola M, Parma G, Bonazzi C, Colombo N, Maneo A, Pittelli MR, Mangioni C: Salvage therapy with ifosfamide and mitoxantrone in advanced ovarian cancer. Ann Oncol 1996;7:419.
25. Di Leo A, Biganzoli L, Bohm S et al: An intensive treatment with mitoxantrone and ifosfamide in second-line therapy of epithelial ovarian cancer. Tumori 1994;80:443.
26. Sutton GP, Blessing JA, Manetta A, Homesley H, McGuire W: Gynecologic Oncology Group studies with ifosfamide. Semin Oncol 1992;6(suppl 12):31.
27. Santoro A, Tursz T, Mouridsen H et al: Doxo-rubicin vs. CyVADic vs. doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: A randomized study of the EORTC, soft tissue and bone sarcoma group. J Clin Oncol 1995;13:1537.
28. Edmonson JH, Ryan LM, Blum RH et al: Randomized comparison of doxorubicin alone vs. ifosfamide plus doxorubicin or mitomycin, doxorubicin and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 1993;11:1269.
29. Antman K, Crowley J, Balcerzak SP et al: An inter-group phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 1993;11:1276.
30. Steward WP, Verweij J, Somers R et al: Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose intensity of chemotherapy in metastatic adult soft tissue sarcomas: A study of the EORTC soft tissue and bone sarcoma group. J Clin Oncol 1993;11:15.
31. Leyvraz S, Bacchi M, Cerny T et al: Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas. Ann Oncol 1998;9:877.